New Firm HalioDx Created from QIAGEN Marseille Buyout

The result of a management buyout of QIAGEN Marseille, HalioDx announced its inception Monday, with a mission statement geared toward pioneering immuno-oncology diagnostics.

HalioDx boasts global licenses on immuno-oncology biomarker patents, including the Immunoscore, which has been shown to significantly improve colon cancer prognostics, and a variety of immune gene expression signatures, said the new company.

HalioDx’s immediate goals include developing standalone assays, hoping to obtain a CE Mark for its Immunoscore within 18 months, and forging agreements with biopharmaceutical firms to develop and register immune companion diagnostics based on its existing license portfolio.

Immuno-oncology is the most active sector in oncology, but there is a noticeable lack of strong predictive biomarkers, the company adds. — Jason Scott